1 **Regulatory-approved Deep Learning/Machine Learning-Based Medical**

2 **Devices in Japan as of 2020: A Systematic Review**

3 Nao Aisu, M.D.¹, Masahiro Miyake, M.D., Ph.D., M.P.H.^{1,2*}, Kohei Takeshita, M.S.³,

4 Masato Akiyama, M.D., Ph.D.^{2,4}, Ryo Kawasaki, M.D., Ph.D., M.P.H.^{2,5}, Kenji Kashiwagi,

5 M.D., Ph.D.^{2,6}, Taiji Sakamoto, M.D., Ph.D.^{2,7}, Tetsuro Oshika M.D., Ph.D.^{2,8}, and Akitaka

6 Tsujikawa, M.D., Ph.D.¹

7

8 **Affiliations**

9 1, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of

10 Medicine, Kyoto, Japan

11 2, Japanese Society of Artificial Intelligence in Ophthalmology, Tokyo, Japan

12 3, Department of Innovation for Medical Information Technology, Jikei University School of

13 Tokyo, Tokyo, Japan

14 4, Department of Ocular Pathology and Imaging Science, Graduate School of Medical

15 Sciences, Kyushu University

16 5, Artificial Intelligence Center for Medical Research and Application, Osaka University

17 Hospital

18 6, Department of Ophthalmology, Faculty of Medicine, University of Yamanashi

19 7, Department of Ophthalmology, Kagoshima University Graduate School of Medical and

20 Dental Sciences

21 8, Department of Ophthalmology, Faculty of Medicine, University of Tsukuba

22

23 ***Corresponding Author:**

24 Masahiro Miyake, M.D., Ph.D. (Kyoto Univ.), M.P.H. (Harvard)

25 Department of Ophthalmology and Visual Sciences

26 Kyoto University Graduate School of Medicine

27 54 Shogoin, Kawahara, Sakyo, Kyoto 606-8507, Japan

28 Tel.: +81-75-751-3248

29 Fax: +81-75-752-0933

30

31 Board Member,

32 Japanese Society of Artificial Intelligence in Ophthalmology

33 3-10-5, Nihonbashi, Chuoku, Tokyo, 1038276, Japan

34 Tel.: +81-3-3510-3741

35 Fax: +81-3-3510-3748

36

37

38

39

40 **Abstract**

41 Machine learning (ML) and deep learning (DL) are changing the world and reshaping the
42 medical field. Thus, we conducted a systematic review to determine the status of
43 regulatory-approved ML/DL-based medical devices in Japan, a leading stakeholder in
44 international regulatory harmonization. Information about the medical devices were obtained
45 from the Japan Association for the Advancement of Medical Equipment search service. The
46 usage of ML/DL methodology in the medical devices was confirmed using public
47 announcements or by contacting the marketing authorization holders via e-mail when the
48 public announcements were insufficient for confirmation. Among the 114,150 medical
49 devices found, 11 were regulatory-approved ML/DL-based Software as a Medical Device
50 (SaMD), with 6 products (54.5%) related to radiology and 5 products (45.5%) related to
51 gastroenterology. The domestic ML/DL-based SaMD were mostly related to health
52 check-ups, which are common in Japan. Our review provides a global overview that can
53 foster international competitiveness and further tailored advancements.

54

55 Introduction

56 The ongoing fourth industrial revolution is mainly driven by the development of information
57 technology, computational power, and deep learning (DL), which is a method of machine
58 learning (ML). The fourth industrial revolution is changing the world in several aspects,
59 including the medical and healthcare fields. Thus, ML/DL-based technologies are expected to
60 transform the healthcare field by providing novel insights from the large amounts of data
61 generated from daily practice.¹⁻⁵ This technological application would improve disease
62 detection or diagnostic accuracy as well as aid the discovery of unprecedented observations
63 for personalized healthcare development.

64 In December 2016, a DL-based algorithm was first introduced in a major medical
65 journal.⁶ The algorithm demonstrated comparable accuracy to ophthalmologists in grading
66 diabetic retinopathy from fundus images. In the following year, reports emerged of a
67 dermatologist-level algorithm for classifying skin cancer into benign or malignant⁷ as well as
68 a pathologist-level algorithm for detecting a metastatic lesion of breast cancer from
69 hematoxylin and eosin-stained tissue sections of lymph nodes.⁸ Consequently, ML/DL
70 attracted considerable attention in the medical field, and more research papers on ML/DL
71 algorithms are being published (**Figure 1**).⁹⁻¹² Unlike the increasing number of ML/DL
72 studies,¹³ there are few regulator-approved, implemented ML/DL algorithms. For example, a
73 recent report noted that only 27 artificial intelligence (AI)/ML algorithms had been approved

74 by the Food and Drug Administration (FDA) in the United States before February 2020.¹⁴

75 Although this discrepancy is due to several reasons, the most prominent is that regulatory
76 authorities require the algorithms to have a high level of reliability in terms of clinical
77 effectiveness and safety; moreover, the regulatory authorities strictly check other factors,
78 such as the reliability of the training data and teacher labels as well as the validity of the
79 validation data and their use cases.

80 Currently, the regulatory authority of each country independently reviews the
81 application of AI-based medical devices because there are no harmonized regulatory
82 standards. However, harmonization is necessary, considering the growing importance of
83 AI-based medical devices that are utilized across borders. The International Council for
84 Harmonization (ICH) was launched in April 1990 to mobilize regulatory authorities and the
85 pharmaceutical industry for the development of global harmonization in pharmaceutical
86 regulations. The ICH was originally founded by the regulatory agencies and industry
87 associations of Europe, Japan, and the United States. The regulatory bodies of each
88 nationality (the European Medicine Agency (EMA), FDA, and the Japanese Pharmaceuticals
89 and Medical Devices Agency (PMDA)) collaborate as leading members of the ICH, which
90 currently includes 17 Members and 32 Observers worldwide. Harmonization in medical
91 devices regulation is also being discussed in the International Medical Device Regulators
92 Forum (IMDRF), of which Japan is also a founding member. IMDRF is expected to lead the

93 global harmonization of the regulatory standards of AI/ML-based medical devices and ensure
 94 that safe, effective, and high-quality devices are developed, registered, and maintained in the
 95 most resource-efficient manner.

96 As this is the dawn of AI-based medical devices, the state of regulatory-approved
 97 AI-based medical devices in each country has not been sufficiently described; for instance,
 98 only one review article has reported the status of the United States.¹⁴ Therefore, we
 99 conducted a systematic review to describe the status of regulatory-approved ML/DL-based
 100 medical devices in Japan, which is a leading member (alongside the United States and
 101 European Union) of international regulatory harmonization.

102

Methods

We conducted a systematic review to determine the state of regulatory-approved ML/DL-based algorithms for medical practice in Japan. Hence, we searched the Japan Association for the Advancement of Medical Equipment search service (JAAME Search) to obtain the data. JAAME Search is a paid electronic database for medical devices and consists of 12 databases, including a database for the laws and regulations, notifications, package insert, approval/certification, etc. We used the approval/certification database, which covers almost all medical devices in Japan. As the first ML/DL-based algorithm in Japan is known to have been approved in December 2018, the search focused on all Software as a Medical Device (SaMD) that were certificated or approved between 1st December, 2018 and 31st October, 2020 (accessed on 23rd November, 2020). From this database, we obtained information such as generic name, marketing name, classification of device, applicant name, application category, application type, date of approval/certification, and approval/certification number.

Furthermore, we selected SaMD that were approved by the Minister of Health, Labor and Welfare because all ML/DL-based SaMD require an approval by the Minister regardless of their classification. This criterion is part of the Japanese regulation for marketing approval of medical devices. In Japan, all Class III and Class IV medical devices and a part of Class II medical devices require approval by the Minister of Health, Labor and

Welfare after a review by the PMDA. Whether a Class II medical device needs an approval or not depends on certification standards: if the Minister of Health, Labor and Welfare has established certification criteria for a medical device category, the device would not need an approval; it would need certification instead. Because of the unprecedented nature of ML/DL-based SaMD, ML/DL-based SaMD currently require an approval in Japan. A comparison of the regulations for marketing approval of medical devices among Japan, US, and EU are summarized in **Figure 2**.

The ML/DL-based SaMD were identified by referring to publicly accessible information, including official websites, press-releases, academic papers, and package inserts. If it was clear from the context that an SaMD employed any ML/DL method (e.g., support vector machine (SVM), random forest, convolutional neural network, recurrent neural network, generative adversarial network) within the scope of the approval, we considered the product as an ML/DL-based algorithm. Thus, devices that adopted ML/DL algorithms outside the scope of the approval were not regarded as ML/DL-based algorithms because the ML/DL used in such devices were irrelevant to diagnosis or lesion detection. Regarding devices for which we could not find publicly accessible information that clearly indicates the usage of ML/DL, we contacted the responsible marketing authorization holder. We asked them (1) to provide us the package insert, (2) whether the SaMD employs artificial intelligence, and (3) to clarify the algorithm employed in the SaMD. If it was still unclear

141 whether the SaMD employed any ML/DL method, we considered the device as a
 142 non-ML/DL-based algorithm. Similarly, if the marketing authorization holder refused to
 143 provide information or did not respond to our e-mail within two weeks, we considered the
 144 device as a non-ML/DL-based algorithm.

145 Finally, we reviewed each of the identified SaMD and summarized their
 146 characteristics.

147

Results

The flow diagram of the result counts is presented in **Figure 3**. From the total of 114,150 approvals or certifications of medical devices registered in the JAAME database, we identified 408 approvals or certifications of program devices. One hundred and twenty SaMD (29.4%) were approved or certificated from December 1st, 2018 to October 31st, 2020. Among these, 39 were approved, consisting of 22 (56.4%) Class II SaMD and 17 (43.6%) Class III SaMD. Nine products were confirmed as ML/DL based on publicly available information, and the other 30 products proceeded to direct query for the marketing authorization holders. We received a reply for 28 products, and among them, 2 were confirmed as ML/DL-based. Consequently, ML/DL-based SaMD were finally identified.

An overview of the ML/DL-based medical devices and algorithms is presented in **Table 1**. The first approval was in December 2018, and it was the only ML/DL-based SaMD approved in the year. This was followed by one approval in 2019 and nine more by the end of October 2020. The number of ML/DL-based SaMD approvals in Japan is rapidly increasing, following the trend of the US as shown in **Figure 4**. The figure illustrates a comparison between the current approval number/year in Japan and the US. The status of the US refers to the study conducted by Benjamens et al.¹⁴ The state of 2020 in the US is shown by the simulated number from the study as it terminated in February 2020 unlike our study that terminated in October 2020. Note that the study conducted by Benjamens et al. evaluated the

number of regulatory-approved AI/ML-based SaMD, whereas we evaluated regulatory-approved ML/DL-based SaMD. This is because the term “artificial intelligence” is too broad in meaning to represent the recent fourth industrial revolution. Even with discrepancy in terminology between the two studies, the figure illustrates the trend of the rapidly increasing Japanese approval number and the trend that follows the recent status of the US.

As shown in Table 1, the medical specialties of regulatory-approved ML/DL-based SaMD were biased to two areas: radiology and gastroenterology, with 6 products (54.5%) and 5 products (45.5%) respectively. All algorithms were “locked” algorithms, i.e., an algorithm that provides the same result each time with the same input and does not change or adapt through real-world practice. Three (27.3%) of the devices were programs developed in foreign companies and imported; the domestic marketing authorization holder applied for approval. The other eight (72.7%) devices were domestically developed. All 11 devices were developed for analyzing medical images, such as X-ray, computed tomography (CT), MRI, and endoscopy. When categorized by their function, three (27.3%) were computer-aided diagnosis (CADx) (EndoBrain[®], EndoBrain-UC[®], EndoBrain-Plus[®]), seven (63.6%) were computer-aided detection (CADE) (EIRL aneurysm[®], FS-AI688[®], InferRead CT Pneumonia[®], AI-Rad Companion[®], EndoBrain-EYE[®], Ali-M3[®], EIRL X-Ray Lung nodule[®]), and the remaining one (9%) combined both functions of CADx and CADE (EW10-EC02[®]).

The first regulatory-approved AI/ML SaMD in Japan was EndoBrain[®], which supports the endoscopists' real-time diagnosis of "neoplastic polyps" or "non-neoplastic polyps" during colonoscopy check-ups. By analyzing the images of the lesion taken with an ultra-magnification colonoscope using SVM algorithm, the possibility of being neoplastic or non-neoplastic is displayed as a percentage. The sensitivity of the device was reportedly 96.8%, and its accuracy was 98.0%.^{15,16} EIRL aneurysm[®] is a CADe software for detecting brain aneurysms (diameter $\geq$ 2 mm) from brain MRA images. This software can support the diagnosis of unruptured cerebral aneurysms at brain check-ups by increasing the sensitivity to detect aneurysms from 68.2% to 77.2%.¹⁷ EndoBrain-UC[®] is a software for predicting the presence or absence of intestinal inflammation (active phase or remission phase) from the ultra-magnified colonoscope images of patients with ulcerative colitis. It could find the remission phase with a sensitivity of 89.5%, specificity of 99.1%, and accuracy of 92%. FS-AI688 is a CADe software for supporting lung nodule detection from lung CT images of suspected lung cancer patients, and it displays marks on possible lung nodules. Both InferRead CT Pneumonia[®] and Ali-M3[®] are DL-based CADe programs for detecting COVID-19 pneumonia from chest CT images in three probability grades; the devices were developed in China. AI-Rad Companion[®] is a series of imaging supportive software, of which "the Chest CT image contract service" is the only product approved in Japan. This software can detect and quantify abnormalities of multiple areas of the body, such as the

lungs, heart, and aorta, from chest CT images. EndoBrain-EYE[®] is a polyp detection program for regular colonoscopy check-ups. When the device detects a candidate lesion for polyp or cancer in the real-time colonoscopy images, it alerts the colonoscopists with sounds and colors on the screen. A sensitivity of 95% and specificity of 89% were reported for the device.¹⁸ EndoBrain-Plus[®] analyzes images of the lesion acquired using an ultra-magnifying colonoscope under methylene blue staining during colonoscopy check-ups. The system displays in real-time the probability of the lesion to be “non-neoplastic,” “adenoma,” “intramucosal carcinoma,” or “invasive carcinoma.” Its performance to detect invasive carcinoma is reported to be 91.8% of sensitivity and 97.3% of specificity. EIRL X-Ray Lung nodule[®] detects suspected pulmonary nodules (5 mm to 30 mm) on chest x-ray images. This CADe is reported to increase a sensitivity to detect lung nodules by 9.9 percentage points for radiologists and 13.1 percentage points for non-specialists. EW10-EC02 is a software for colonoscopy, which supports lesion detection, such as polyps, by framing the suspected lesion on the monitor and alerting with sounds. The device can also differentiate the lesion as neoplastic or non-neoplastic. These functionalities of the device operate in real-time during colonoscopy.

Discussion

The implementation of ML/DL in medical devices is advancing swiftly as ML/DL demonstrates high prospects in improving clinical outcomes and public health, and it is cost-effective.^{19,20} In these early stages of the ML/DL era, we aimed to highlight the state of regulatory-approved ML/DL-based SaMD in Japan whose regulatory body, PMDA, is one of the leading members of international regulatory harmonization alongside Europe's EMA and the United States' FDA. Our study showed that 11 AI/ML-based SaMD had been approved in Japan as of October 2020.

In comparison to the US approval status reported by Benjamens, et.al.¹⁴, the field of radiology is a trendsetter of ML/DL-based SaMD in both countries as SaMD related to radiology was the most approved both in Japan and the US with 54.5% and 72.4%, respectively. This is probably due to the image-intensive nature of radiology, and DL technology has high affinity to imaging. Conversely, a prominent feature of the Japanese approval status is that gastroenterology was second (45.5%) to radiology in the implementation of ML/DL in the medical field, whereas the FDA-approved devices next to radiology were in cardiology, internal medicine/endocrinology, neurology, ophthalmology, emergency medicine, and oncology. The EndoBrain[®] series occupies four of five regulatory-approved endoscopy-related ML/DL-based SaMD, which were developed with funding from the Japan Agency for Medical Research and Development (AMED), technical

support from Cybernet, and endoscopic technology and commercialization from Olympus. Olympus is a Japanese company occupying 70% of the world market share for endoscopes. The technology to enhance image resolution with ultra-magnification colonoscopes and their powerful sales channel is believed to have been a major driving force behind the implementation of ML/DL technology in this field. Another unique device among the domestic devices is EIRL aneurysm[®], an algorithm to detect “unruptured” aneurisms from MRA images. Although several algorithms have been developed in other countries that support the detection of acute lesion, such as cerebral injury or hemorrhage using MRI, EIRL aneurysm[®] is unique because it focuses on the precursor lesion placing MRI as a health check-up tool. This was approved relatively early, meaning the demand for the product was high. As Japan is a global leader in MRI possession, “Brain check-up” is becoming more popular among Japanese citizens because of its accessibility and affordability. This situation likely facilitated the implementation of this technology.

The first autonomous diagnostic device approved by the FDA (April 2018) was a diabetic retinopathy screening device (IDx-DR[®], Digital Diagnostics) that was recently followed by a similar device approved in August 2020 (EyeArt[®], EYENUK). In contrast, there have been no regulatory-approved ML/DL-based SaMD in the field of ophthalmology in Japan. This difference may be related to the social need as Japan has easier medical access with the availability of several medical practitioners in local clinics as well as universal

health coverage. Nevertheless, as the Japanese Ocular Imaging registry was established as a platform for industry-university collaboration, similar to the Intelligent Research in Sight registry of the American Academy of Ophthalmology, the number of ML/DL-based ophthalmological device will hopefully increase. Building a platform for AI utilization is an important issue in every country, and Japan is moving toward the realization.

Apparently, AI-based SaMD are closely related to society. Thus, focusing on the public needs or industrial strengths of each country can lead to a more competitive and unique development when seeking a global market. For example, because of the increasing public health awareness and easy access to medicine, health check-ups are popular in Japan. Most ML/DL-based SaMD approved in Japan were programs that targeted check-ups rather than a specialized or specific medical practice. Moreover, the high proportion of ML/DL-based SaMD related to endoscopy in Japan reflects Japan's industrial strength in endoscopic systems. It is important for each country to scrutinize the public demand and industrial situation to facilitate the implementation of AI. Knowledge of the developmental background is also crucial when considering the implementation of a foreign device as most ML/DL-based medical devices will probably be exported after domestic commercialization. Imported products may not work well due to differences in backgrounds (e.g., social needs, health insurance system, etc.), even if the product is dominant in other countries. Therefore, the approval situation and background information of the innovation can be an important

information that suggest how to adopt imported ML/DL-based devices. Therefore, it is worthwhile to investigate the developmental situation of SaMD in each country.

In this systematic review, we report on the regulatory-approved ML/DL-based SaMD in Japan. Our review provides an overview of the global developmental situation of ML/DL-based medical devices, considering the current lack of relevant information about such devices. As ML/DL-based SaMD are closely related to the industrial and cultural backgrounds of each country, development that is focused on the strengths of each country can lead to international competitiveness. Additionally, the maximization of the capabilities of AI requires a consideration of the strengths in each country and creation of a platform for more active developments.

Figure Legend

Figure 1. Transition of the number of publications regarding machine learning or deep learning in PubMed.

(A) Transition of the number of machine-learning-related publications. The search query was (Machine learning) AND (("2015/1/1"[Date - Publication] : "2020/12/31"[Date - Publication])) (accessed at 2, February, 2021). (B) Transition of the number of deep-learning-related publications. The search query was (Deep learning) AND (("2015/1/1"[Date - Publication] : "2020/12/31"[Date - Publication])) (accessed at 2, February, 2021). Publications regarding machine learning or deep learning are rapidly increasing in PubMed.

Figure 2. Comparison of the regulation for marketing approval of medical devices among the United States, Japan, and European Union.

The figure illustrates the regulatory status of the three nationalities based on the classification of medical devices. In Japan, medical devices of class III or more and those of class II for which certification standards do not exist (e.g., artificial intelligence (AI) medical devices as of 2020) require the review of Pharmaceuticals and Medical Devices Agency as well as the approval of the Ministry of Health, Labour, and Welfare. A software that corresponds to class I medical device is not treated as medical device in Japan. FDA: Food and Drug

Administration; PMDA: Japanese Pharmaceuticals and Medical Devices Agency; MHLW:
Ministry of Health, Labour, and Welfare.

**Figure 3. Flow diagram of identifying the applicable Software as a Medical Device
(SaMD).**

From the total of 114,150 medical devices in the Japan Association for the Advancement of
Medical Equipment (JAAME) search database accessed on 23rd November 2020, we have
identified 408 SaMD. Among these, 120 were certificated or approved from December 1st,
2018 to October 31st, 2020 and 39 were approved SaMD. Products with a clear statement of
ML/DL usage or with the confirmation from the marketing authorization holder were
considered as ML/DL-based. 11 ML/DL-based SaMD were finally identified.

**Figure 4. Comparison of the approval status of machine learning/deep learning-based
software as a medical device (SaMD) between Japan and the United States.**

The figure illustrates a comparison between the current approval number/year in Japan and
the US. The status of the US refers to the study conducted by Benjamens et al.¹⁴ The state of
2020 in the US is shown by the simulated number from the study as it terminated in February
2020 unlike our study that terminated in October 2020. Note that the study conducted by
Benjamens et al. evaluated the number of regulatory-approved AI/ML-based SaMD, whereas

we evaluated regulatory-approved ML/DL-based SaMD. This is because the term “artificial intelligence” is too broad in meaning to represent the recent fourth industrial revolution. Even with discrepancy in terminology between the two studies, the figure illustrates the trend of the rapidly increasing Japanese approval number and the trend that follows the recent status of the US.

Financial Support: This research was supported by AMED under Grant Number JP20vk0124003. This research was also supported by MHLW ICT infrastructure establishment and implementation of artificial intelligence for clinical and medical research program, Grant Number JP20AC0201.

Conflict of Interest: No conflicting relationship exists for any author.

Acknowledgements

We would like to thank the marketing authorization holders for collaborating by answering our query on the early stage of this work.

349

350 **Author Contributions**

351 NA, MM were involved in study design. NA, KT were involved in data collection. NA, MM,
 352 MA, RK, KK, TS, TO, and AT were involved in data interpretation. All authors critically
 353 revised the manuscript, approved the manuscript to be published, and agreed to be
 354 accountable for all aspects of the work ensuing that questions related to the accuracy or
 355 integrity of any part of the work are appropriately investigated and resolved.

356

357

358 **Data Availability**

359 Data that support the findings of this study are available in the JAMME search repository,
 360 <https://search.jaame.or.jp/jaames/login.php>

361

References

- 1 Hosoda, Y. *et al.* Deep phenotype unsupervised machine learning revealed the significance of pachychoroid features in etiology and visual prognosis of age-related macular degeneration. *Sci. Rep.* **10**, 18423, doi:10.1038/s41598-020-75451-5 (2020).
- 2 Hosoda, Y. *et al.* Keratoconus-susceptibility gene identification by corneal thickness genome-wide association study and artificial intelligence IBM Watson. *Commun. Biol.* **3**, 410, doi:10.1038/s42003-020-01137-3 (2020).
- 3 Stead, W. W. Clinical Implications and Challenges of Artificial Intelligence and Deep Learning. *JAMA* **320**, 1107-1108, doi:10.1001/jama.2018.11029 (2018).
- 4 Topol, E. J. High-performance medicine: the convergence of human and artificial intelligence. *Nat. Med.* **25**, 44-56, doi:10.1038/s41591-018-0300-7 (2019).
- 5 Verghese, A., Shah, N. H. & Harrington, R. A. What This Computer Needs Is a Physician: Humanism and Artificial Intelligence. *JAMA* **319**, 19-20, doi:10.1001/jama.2017.19198 (2018).
- 6 Gulshan, V. *et al.* Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. *JAMA* **316**, 2402-2410, doi:10.1001/jama.2016.17216 (2016).
- 7 Esteva, A. *et al.* Dermatologist-level classification of skin cancer with deep neural networks. *Nature* **542**, 115-118, doi:10.1038/nature21056 (2017).

381 8 Bejnordi, B. E. *et al.* Diagnostic Assessment of Deep Learning Algorithms for
382 Detection of Lymph Node Metastases in Women With Breast Cancer. *JAMA* **318**,
383 2199-2210, doi:10.1001/jama.2017.14585 (2017).

384 9 Phan, S. *et al.* Evaluation of deep convolutional neural networks for glaucoma
385 detection. *Jpn. J. Ophthalmol.* **63**, 276-283, doi:10.1007/s10384-019-00659-6 (2019).

386 10 Otsuki, R. *et al.* Deep Learning Model to Predict Postoperative Visual Acuity from
387 Preoperative Multimedia Ophthalmic Data. *Adv. Biomed. Eng.* **9**, 241-248,
388 doi:10.14326/abe.9.241 (2020).

389 11 Kaul, V., Enslin, S. & Gross, S. A. History of artificial intelligence in medicine.
390 *Gastrointest. Endosc.* **92**, 807-812, doi:10.1016/j.gie.2020.06.040 (2020).

391 12 Caruana, R. *et al.* in *Proceedings of the 21th ACM SIGKDD International Conference*
392 *on Knowledge Discovery and Data Mining - KDD '15* 1721-1730 (2015).

393 13 Litjens, G. *et al.* A survey on deep learning in medical image analysis. *Med. Image*
394 *Anal.* **42**, 60-88, doi:10.1016/j.media.2017.07.005 (2017).

395 14 Benjamens, S., Dhunoo, P. & Mesko, B. The state of artificial intelligence-based
396 FDA-approved medical devices and algorithms: an online database. *NPJ Digit. Med.*
397 **3**, 118, doi:10.1038/s41746-020-00324-0 (2020).

398 15 Kudo, S. E. *et al.* Artificial Intelligence-assisted System Improves Endoscopic
399 Identification of Colorectal Neoplasms. *Clin. Gastroenterol. Hepatol.* **18**, 1874-1881

400 e1872, doi:10.1016/j.cgh.2019.09.009 (2020).

401 16 Mori, Y. *et al.* Real-Time Use of Artificial Intelligence in Identification of Diminutive
402 Polyps During Colonoscopy: A Prospective Study. *Ann. Intern. Med.* **169**, 357-366,
403 doi:10.7326/M18-0249 (2018).

404 17 Ueda, D. *et al.* Deep Learning for MR Angiography: Automated Detection of Cerebral
405 Aneurysms. *Radiology* **290**, 187-194, doi:10.1148/radiol.2018180901 (2019).

406 18 Misawa, M. *et al.* Artificial Intelligence-Assisted Polyp Detection for Colonoscopy:
407 Initial Experience. *Gastroenterology* **154**, 2027-2029 e2023,
408 doi:10.1053/j.gastro.2018.04.003 (2018).

409 19 Matheny, M. E., Whicher, D. & Israni, S. T. Artificial Intelligence in Health Care: A
410 Report From the National Academy of Medicine. *JAMA* **323**, 509-510,
411 doi:10.1001/jama.2019.21579 (2020).

412 20 London, A. J. Artificial Intelligence and Black-Box Medical Decisions: Accuracy
413 versus Explainability. *Hastings Cent. Rep.* **49**, 15-21, doi:10.1002/hast.973 (2019).

414

415

416

417

A

Papers related to “Machine learning”

B

Papers related to “Deep learning”

Country [Regulator]	Medical Devices Classification				
The United States [FDA]	Class I	Class II		Class III	
Japan [Review: PMDA] [Approval: MHLW]	Class I	Class II		Class III	Class IV
The European Union [Notification Body]	Class I	Class II a	Class II b		
			Class III		

Medical devices for which certification standards do not exist [e.g., AI medical devices as of 2020]

needs approval

needs third-party certification

needs notification / self-certification

Total approvals/certifications of
medical devices
registered in JAMME database
N=114,150

Total approvals/certifications of SaMD
N=408

Approved/certificated during
targeted period (Dec 2018 to Oct 2020)
N=120

Approval
N=39

**Able to confirm the usage of
ML/DL from public
announcement**

YES

**ML/DL-based SaMD
N=9**

NO

Insufficient information
N=30

**Able to confirm the usage of
ML/DL by contacting
marketing authorization
holder via Email**

YES

**ML/DL-based SaMD
N=2**

NO

Unable to confirm the usage of ML/DL
N=28

Annual trend of regulatory-approved AI-based SaMD

Table1. Overview of the ML/DL-based medical devices and algorithms approved in Japan

No.	Device name	Short description	Class	Company name	Application distinction	Approval date	PMDA approval number	Medical specialty	Algorithm	CAD	Country	Image type
1	EW10-EC02	Lesion detection and diagnosis during colonoscopy	III	FUJIFILM	approved	2-Sep-20	30200BZX00288000	Gastroenterology	deep learning	CADe +CADx	Japan	endoscopy
2	EIRL X-Ray Lung nodule	Lung cancer detection	II	LPIXEL	approved	20-Aug-20	30200BZX00269000	Radiology	deep learning (CNN)	CADe	Japan	X-ray
3	EndoBRAIN□Plus	Pathological prediction during colonoscopy	III	CYBERNET	approved	15-Jul-20	30200BZX00235000	Gastroenterology	Machine learning (SVM)	CADx	Japan	endoscopy
4	Ali-M3	COVID-19 pneumonia detection	II	MIC Medical Corp.	approved	29-Jun-20	30200BZX00212000	Radiology	deep learning	CADe	China	CT
5	EndoBRAIN□EYE	Polyp detection during colonoscopy	II	CYBERNET	approved	29-Jun-20	30200BZX00208000	Gastroenterology	deep learning	CADe	Japan	endoscopy
6	AI-Rad companion (Chest CT)	Detects and quantifies abnormalities of the chest CT	II	Siemens Healthineers Japan	approved	19-Jun-20	30200BZX00202000	Radiology	deep learning	CADe	Germany US	CT
7	InferRead CT Pneumonia	COVID-19 pneumonia detection	II	CES decartes	approved	3-Jun-20	30200BZX00184000	Radiology	deep learning (CNN)	CADe	China	CT
8	FS-AI688	Lung cancer detection	II	FUJIFILM	approved	8-May-20	30200BZX00150000	Radiology	deep learning	CADe	Japan	CT
9	EndoBRAIN□UC	Inflammation assessment support for Ulcerative Colitis	III	CYBERNET	approved	27-Apr-20	30200BZX00136000	Gastroenterology	machine learning (SVM)	CADx	Japan	endoscopy
10	EIRL aneurysm	Cerebral aneurysm detection	II	LPIXEL	approved	17-Sep-19	30100BZX00142000	Radiology	deep learning (CNN)	CADe	Japan	MRI
11	EndoBRAIN	Pathological prediction during colonoscopy	III	CYBERNET	approved	6-Dec-18	23000BZX00372000	Gastroenterology	machine learning (SVM)	CADx	Japan	endoscopy

CNN: convolutional neural network, SVM: support vector machine, CADe: computer-aided detection, CADx: computer-aided diagnosis; PMDA: Pharmaceuticals and Medical Devices Agency (Japan)